Vet Med - Czech, 2019, 64(2):92-99 | DOI: 10.17221/70/2018-VETMED

Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case reportCase Report

Joong Hyun Song1, Tae Sung Hwang1, Hee Chun Lee1, Do Hyeon Yu1, Byung Joon Seung2, Jung Hyang Sur2, Dong In Jung*,1
1 Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju, Republic of Korea
2 College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea

A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem. Management with imatinib mesylate, prednisolone and hydroxyurea were initiated and resulted in complete resolution of the clinical signs. In regular magnetic resonance imaging scans, the overall appearance of the lesions deteriorated but improved again after an increase in the imatinib mesylate dose. The patient had not shown any neurological signs until death and survived for 1052 days after initial presentation. On histopathological examination, the patient was diagnosed with disseminated granulomatous meningoencephalitis involving the cerebrum and brainstem. Immunohistochemical staining was performed on the five types of tyrosine kinase (PDGFR-α, PDGFR-ß, VEGFR-2, c-Kit and c-Abl proteins), which constitute therapeutic targets for conventional multitargeted tyrosine kinase inhibitors. The immunohistochemical analysis revealed that all these tyrosine kinases were expressed in the brain samples. The present report describes the first case of the use of imatinib mesylate therapy for granulomatous meningoencephalitis in the dog. Therapy with imatinib mesylate plus glucocorticoids appears promising as a new therapeutic intervention in meningoencephalitis of unknown aetiology.

Keywords: dog; immunohistochemical staining; magnetic resonance imaging; unknown aetiology; tyrosine kinase; tyrosine kinase inhibitor

Published: February 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Song JH, Hwang TS, Lee HC, Yu DH, Seung BJ, Sur JH, Jung DI. Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report. Vet Med - Czech. 2019;64(2):92-99. doi: 10.17221/70/2018-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K, Umeda N, Tanaka Y, Hayashi T, Goto D, Ito S (2011): Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Modern Rheumatology 21, 267-275. Go to original source...
    2. Azizi G, Mirshafiey A (2013): Imatinib mesylate: An innovation in treatment of autoimmune diseases. Recent Patents on Inflammation & Allergy Drug Discovery 7, 259-267. Go to original source... Go to PubMed...
    3. Azizi G, Haidari MR, Khorramizadeh M, Naddafi F, Sadria R, Javanbakht MH, Sedaghat R, Zavareh FT, Mirshafiey A (2014): Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iranian Journal of Allergy, Asthma and Immunology 13, 198-206.
    4. Bonkobara M (2015): Dysregulation of tyrosine kinases and use of imatinib in small animal practice. The Veterinary Journal 205, 180-188. Go to original source... Go to PubMed...
    5. Braund K (1985): Granulomatous meningoencephalomyelitis. Journal of the American Veterinary Medical Association 186, 138-141.
    6. Coates JR (2007): Emerging treatments for granulomatous meningoencephalomyelitis (gme). Advances in Small Animal Medicine and Surgery 20, 1-3. Go to original source...
    7. Coffey G, Deguzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D (2012): Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics 340, 350-359. Go to original source... Go to PubMed...
    8. Eklund KK, Joensuu H (2003): Treatment of rheumatoid arthritis with imatinib mesylate: Clinical improvement in three refractory cases. Annals of Medicine 35, 362-367. Go to original source... Go to PubMed...
    9. Fisher M (2002): Disseminated granulomatous meningoencephalomyelitis in a dog. The Canadian Veterinary Journal 43, 49-51.
    10. Granger N, Smith PM, Jeffery ND (2010): Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: A systematic review of 457 published cases from 1962 to 2008. The Veterinary Journal 184, 290-297. Go to original source... Go to PubMed...
    11. Greer K, Wong A, Liu H, Famula T, Pedersen N, Ruhe A, Wallace M, Neff M (2010): Necrotizing meningoencephalitis of pug dogs associates with dog leukocyte antigen class ii and resembles acute variant forms of multiple sclerosis. Tissue Antigens 76, 110-118. Go to original source... Go to PubMed...
    12. Inayat MS, El-Amouri IS, Bani-Ahmad M, Elford HL, Gallicchio VS, Oakley OR (2010): Inhibition of allogeneic inflammatory responses by the ribonucleotide reductase inhibitors, didox and trimidox. Journal of Inflammation 7, doi: 10.1186/1476-9255-7-43. Go to original source... Go to PubMed...
    13. Jung HW, Lee HC, Kim JH, Jang HM, Moon JH, Sur JH, Ha J, Jung DI (2014): Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog. The Journal of Veterinary Medical Science 76, 1545-1548. Go to original source... Go to PubMed...
    14. Lori F (1999): Hydroxyurea and hiv: 5 years later-from antiviral to immune-modulating effects. AIDS 13, 1433- 1442. Go to original source... Go to PubMed...
    15. Matsuki N, Fujiwara K, Tamahara S, Uchida K, Matsunaga S, Nakayama H, Doi K, Ogawa H, Ono K (2004): Prevalence of autoantibody in cerebrospinal fluids from dogs with various cns diseases. The Journal of Veterinary Medical Science 66, 295-297. Go to original source... Go to PubMed...
    16. Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G (2014): Receptor tyrosine kinase and tyrosine kinase inhibitors: New hope for success in multiple sclerosis therapy. Innovations in Clinical Neuroscience 11, 23-36.
    17. Munana KR, Luttgen PJ (1998): Prognostic factors for dogs with granulomatous meningoencephalomyelitis: 42 cases (1982-1996). Journal of the American Veterinary Medical Association 212, 1902-1906. Go to original source...
    18. O'Neill EJ, Merrett D, Jones B (2005): Granulomatous meningoencephalomyelitis in dogs: A review. Irish Veterinary Journal 58, 86-92. Go to original source... Go to PubMed...
    19. Park E, Uchida K, Nakayama H (2012): Comprehensive immunohistochemical studies on canine necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and granulomatous meningoencephalomyelitis (GME). Veterinary Pathology 49, 682-692. Go to original source... Go to PubMed...
    20. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS (2012): Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology 106, 409-415. Go to original source... Go to PubMed...
    21. Shah GD, Silver JS, Rosenfeld SS, Gavrilovic IT, Abrey LE, Lassman AB (2007): Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. Journal of Neuro-Oncology 85, 217- 222. Go to original source... Go to PubMed...
    22. Sospedra M, Martin R (2016): Immunology of multiple sclerosis. Seminars in Neurology 36, 115-127. Go to original source... Go to PubMed...
    23. Suzuki M, Uchida K, Morozumi M, Hasegawa T, Yanai T, Nakayama H, Tateyama S (2003): A comparative pathological study on canine necrotizing meningoencephalitis and granulomatous meningoencephalomyelitis. The Journal of Veterinary Medical Science 65, 1233-1239. Go to original source... Go to PubMed...
    24. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV (2002): Drug responses of imatinib mesylateresistant cells: Synergism of imatinib with other chemotherapeutic drugs. Leukemia 16, 2349-2357. Go to original source... Go to PubMed...
    25. Vermersch P, Benrabah R, Schmidt N, Zeehir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O (2012): Masitinib treatment in patients with progressive multiple sclerosis: A randomized pilot study. BMC Neurology 12, doi: 10.1186/1471-2377-12-36. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content